Evoke Wealth’s Emergent Biosolutions EBS Stock Holding History

Evoke Wealth’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-917	Closed	-$49.5K	–	1194
2019 Q4	$49.5K	Sell	917 -39	-4%	-$2.12K	0.01%	415
2019 Q3	$50K	Buy	+956	New	+$44.5K	0.01%	464

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Evoke Wealth's EBS Position: Q1 2020 in Review

Evoke Wealth sold out of Emergent Biosolutions (EBS) in Q1 2020, closing a stake of 917 shares — an estimated $49.5K sold.

Evoke Wealth first reported a position in EBS in Q3 2019 and held it in 2 quarters. The position peaked at $50K in Q3 2019. 263 funds tracked by Wall St. Rank hold EBS as of Q1 2020.

Evoke Wealth reported no remaining Emergent Biosolutions position as of Q1 2020 after selling out during the quarter.
Evoke Wealth sold 917 Emergent Biosolutions shares in Q1 2020, an estimated $49.5K.
Evoke Wealth first reported a position in Emergent Biosolutions in Q3 2019 and held it in 2 quarters.
Evoke Wealth's Emergent Biosolutions position peaked at $50K in Q3 2019.
263 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2020.

Based on Evoke Wealth's 13F filing for Q1 2020, filed 7 May 2020.